Press Releases

Date Title  
Toggle Summary New Study Shows Benefit of Using Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer
Breakthrough blood test detects relapse earlier and helps patients avoid unnecessary clinic visits with GI Expanded Access Program SAN CARLOS, Calif. , April 2, 2020 /PRNewswire/ -- A new, peer-reviewed case study published in JCO Precision Oncology 1 demonstrates the unique ability of Signatera
Toggle Summary Natera Provides Remote Access to Tests Without Requiring Live Office Visits
Enabling continuity of care while allowing patients to stay home SAN CARLOS, Calif. , March 19, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities
Toggle Summary Natera to Showcase Leadership in Cell-Free DNA at CEoT Conference
SAN CARLOS, Calif. , March 4, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will be participating in the Cutting Edge of Transplantation (CEoT) conference taking place March 5-7, 2020 in Phoenix, Arizona .
Toggle Summary Natera to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif. , March 3, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast live presentations at the Cowen and Company 40 th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 8:20
Toggle Summary Natera Receives Favorable Medicare Reimbursement Pricing for Prospera™
SAN CARLOS, Calif. , March 3, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75 .
Toggle Summary Natera Reports Fourth Quarter and Year 2019 Financial Results
SAN CARLOS, Calif. , Feb. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an update on recent
Toggle Summary Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call
SAN CARLOS, Calif. , Feb. 19, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019 , after the market close on February 26, 2020 .
Toggle Summary Natera Files False Advertising Counterclaim Against CareDx
CareDx's advertising obfuscates AlloSure's poor performance SAN CARLOS, Calif. , Feb. 18, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it has filed suit against CareDx for false advertising in the U.S.
Toggle Summary Natera Files Suit Against ArcherDX for Patent Infringement
SAN CARLOS, Calif. , Jan. 27, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent"). The complaint was filed in the U.S. District Court of Delaware .
Toggle Summary National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer
Pivotal Study of 1500 Patients Could Lead to Change in Practice Guidelines SAN CARLOS, Calif. , Jan. 15, 2020 /PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan , a prospective,

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.